Affordable large-scale DNA variation studies for every DNA researcher

HARDERWIJK, THE NETHERLANDS - Sep 24, 2015 - Today, GENALICE announced the global launch date of Population Calling, a new analysis module and part of their GENALICE MAP Next-Generation Sequencing (NGS) Data Analysis Suite. In a LIVE webinar event scheduled in two weeks from today, on October 8, the company will reveal the unique capabilities to improve individual patient results and discover disease specific DNA changes at significantly reduced cost and time to result.

Hans Karten, CEO/CTO of GENALICE explains: Single sample variant detection is the standard approach to determine DNA changes in an individual patient that may be related to disease. Population Calling, also referred to as Joint Calling or Pooled Calling by others, is an improved NGS data analysis methodology in which multiple samples from a cohort study are examined in a single variant detection analysis. The aggregate information of all samples is used to improve the sensitivity and precision to detect all DNA changes in a single sample. This means that individual patients diagnosis is enhanced using the consensus result of an entire cohort. Population Calling provides a strong context for new biomarker discoveries in research and high confidence diagnosis in clinical application.

Nationwide studies, like the last week announced U.S. National Institutes of Health (NIH) framework, in which a cohort of one million or more Americans is studied, aim to expand the knowledge and practice of precision medicine. In phase III clinical drug development studies, cohort sizes range from 400 to 800 patients. And larger scale cohort studies easily include 5,000 to 10,000 patient samples.

In these and many other cases, Population Calling is considered of high importance, but it also creates a true big data challenge. As a result, to date, Population Calling using existing analysis tools, has been the preserved territory of a select group of large institutes and companies that have extensive knowledge, resources, budget and patience to wait for results.

Jos Lunenberg, GENALICE Chief Business Officer, comments: It is time to make Population Calling available to every single genomics researcher at an unprecedented price point and analysis speed. We are collaborating with the expert teams from deCODE genetics and Mount Sinai Hospital (NYC). In two weeks we will remove the covers in a LIVE online event. We have chosen this date, as it coincides with the American Society of Human Genetics (ASHG) 2015 Annual Meeting in Baltimore (MA, USA), where thousands of genetics researchers are gathering and our team is present with a booth.

Lunenberg continues: We have an incredible opportunity to advance research and make new medical breakthroughs through improved diagnosis and precision medicine, which tailors disease prevention and treatment to individuals driven by the analysis of their molecular profiles. GENALICE is proud to contribute to this important endeavor.

About GENALICE

GENALICE is a highly innovative biomedical big data solutions company, with global headquarters in the Netherlands. GENALICE designs and builds groundbreaking software solutions for ultra-fast, highly accurate and cost-effective DNA data processing and analysis. The software is deployed on general-purpose hardware or flexible cloud. With GENALICE MAP, the company has introduced the first Next-Generation Sequencing (NGS) data processing pipeline with true population power. By partnering with world-renowned research institutes and healthcare companies, GENALICE is committed to unlocking the potential of whole genome, exome and transcriptome sequencing for biomarker discovery and clinical application.

More information on GENALICE can be found at www.genalice.com.

For more information, please contact:

GENALICE B.V.
Jos Lunenberg
Chief Business Officer
jos.lunenberg@genalice.com
Twitter: GenaliceDNA